AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2022
Nov 11, 2022
32159_dirs_2022-11-10_a03fa816-6b0d-495b-ba2c-088eac8f55f7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2022-11-08
Reporting Person: SCHNEIDER PHILLIP M (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-11-08 | Stock option (right to buy) | $0.84 | A | 153647 | Acquired | 2029-07-05 | Common Stock (153647) | Direct |
| 2022-11-08 | Stock option (right to buy) | $1.44 | A | 76823 | Acquired | 2031-12-14 | Common Stock (76823) | Direct |
Footnotes
F1: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.
F2: Received in exchange for a stock option to acquire 130,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") with the exercise price of $0.99 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement").
F3: Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.
F4: The shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments measured from the vesting commencement date.
F5: Received in exchange for a stock option to acquire 65,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement.